[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100280748":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":30,"locations":40,"responsibleParty":58,"collaborators":60,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":10,"eligibilityCriteria":73,"healthyVolunteers":70,"sex":74,"minAge":75,"maxAge":10,"enrollmentInfo":76,"targetDuration":10,"studyType":79,"phases":10,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Center for International Blood and Marrow Transplant Research","NETWORK",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Hematopoietic Stem Cell Transplant (HCT)",null,"Patients undergoing alloHCT in a US transplant center and reported to the CIBMTR",[13],"Other: Hematopoietic Stem Cell Transplant",{"label":15,"type":10,"description":16,"interventionNames":10},"Non-HCT","Historical non-transplant controls collected from 14 US academic centers. Centers will provide data on all consecutive patients with PMF, post-ET MF, or post-PV MF referred to their institutions between 2000 and 2012.",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"OTHER","Hematopoietic Stem Cell Transplant","This observational study will compare outcomes of prospectively enrolled HCT recipients with outcomes of a cohort of age-matched non-HCT controls.",[9],[24,28],{"name":25,"affiliation":26,"role":27},"Wael Saber, MD","Medical College of Wisconsin","STUDY_CHAIR",{"name":29,"affiliation":26,"role":27},"Laura Michaelis, MD",[31,36],{"name":32,"role":33,"phone":34,"phoneExt":10,"email":35},"Patricia Steinert, PhD","CONTACT","414-805-0700","psteinert@mcw.edu",{"name":37,"role":33,"phone":38,"phoneExt":10,"email":39},"Stephanie Farnia","763-406-8640","sfarnia@nmdp.org",[41],{"facility":5,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","Minneapolis","Minnesota","55401","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-93.26384,44.97997,{"lat":52,"lon":51},[55],{"name":56,"role":33,"phone":10,"phoneExt":10,"email":57},"Michael Tierney","DatabaseIRB@NMDP.org",{"type":59,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[61,63,66],{"name":62,"class":19},"National Marrow Donor Program",{"name":64,"class":65},"National Institutes of Health (NIH)","NIH",{"name":67,"class":65},"National Cancer Institute (NCI)","100280748","prospective-assessment-of-allogeneic-hematopoietic-cell-transplantation-in-patients-with-myelofibrosis-100280748",false,"NCT02934477","Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis","Inclusion Criteria:\n\n* Patients fulfilling the following criteria will be eligible for inclusion in the study:\n\n  * PMF, post-ET MF, or post-PV MF.\n  * Int-2 or high-risk disease as determined by the DIPSS.\n  * Age ≥55 at the time of DIPSS assessment.\n  * For the alloHCT arm:\n\n    * Donors must be a 6\u002F6 HLA-matched related donors, defined by Class I (HLA-A and -B) intermediate resolution or high resolution DNA-based typing and Class II (HLA-DRBI) at high resolution DNA-based typing (but not monozygotic twins) OR an 8\u002F8 HLA-A, -B, -C, and -DRB1 at high resolution DNA-based typing matched unrelated donor identified through the National Marrow Donor Program (NMDP)\u002FBe The Match. Donors must meet institutional or NMDP\u002FBe The Match selection criteria; there is no age restriction for sibling donors.\n    * Both peripheral blood stem cells and bone marrow grafts are allowed.\n    * All conditioning regimen intensities are allowed.\n    * All GVHD prophylaxis regimens are allowed.\n  * Haploidentical donors are allowed in the Haploidentical Donor Study\n\nExclusion Criteria:\n\n* Patients with the following criteria will be ineligible for entry into the study:\n\n  * AlloHCT using umbilical cord blood unit(s) or HLA-mismatched adult donors (\\\u003C 6\u002F6 HLA alleles for related and \\\u003C 8\u002F8 HLA alleles for unrelated).\n  * Overlap syndromes.","ALL","55 Years",{"count":77,"type":78},650,"ESTIMATED","OBSERVATIONAL","This observational study will compare outcomes of a prospectively-enrolled cohort of Hematopoietic Stem Cell Transplant (HCT) recipients with outcomes of a cohort of age-matched historical non-HCT controls. Patients undergoing alloHCT will receive HCT in a US transplant center and be reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) using well-established CIBMTR report forms and data collection procedures as well as a study-specific supplemental form. Data on the historical non-HCT controls will be collected at 14 US academic centers. These centers will provide data on all consecutive patients with PMF, post-ET MF, or post-PV MF referred to their institutions between 2000 and 2012.",[82],"Myelofibrosis",[82,20,84],"Medicare","2023-08-29",{"date":87,"type":88},"2023-08-30","ACTUAL",{"date":90,"type":10},"2016-11",{"date":92,"type":78},"2027-10",{"name":5,"class":6},1]